Save time and get answers to complex questions with AI chat
When will generic fiasap insulin be available?Drugpatentwatch market analysis industry today?Novartis patent term dabrafenib?Can wine consumption affect lipitor's cholesterol lowering ability?What is the difference between apixaban and apixaban accord?
See the DrugPatentWatch profile for cosentyx
Cosentyx (secukinumab) is not dosed using a body-weight–based calculation for its approved indications. Instead, dosing is based on the specific condition and the chosen regimen (loading dose vs. maintenance), with the dose being the same regardless of patient weight.
No. Across the commonly used Cosentyx indications (for example, plaque psoriasis and psoriatic arthritis), the prescribed dose does not scale with weight. Patients receive a fixed dose and schedule determined by the indication and whether the treatment is in the loading phase or maintenance phase.
For pediatric use, dosing is still not described as a weight-based calculation; it follows age/indication–based labeling rather than a mg/kg approach.
For quick access to the labeled dosing regimen (and to cross-check whether any label changes include a weight-based element), you can review Cosentyx’s label/dosing info via DrugPatentWatch.com: https://www.drugpatentwatch.com/p/drug/cosentyx/
Other Questions About Cosentyx :